On April 21, Huadong Pharmaceutical (000963) recently released its 2020 annual report. During the reporting period, the company achieved an operating revenue of 33683058759.75 yuan, a year-on-year decrease of 4.97%; the net profit attributable to shareholders of listed companies was 2819861203.63 yuan, a year-on-year increase of 0.24%.
During the reporting period, the net cash flow from operating activities was 3411447747.56 yuan, and the net assets attributable to shareholders of listed companies were 14619821308.60 yuan by the end of 2020.
In 2020, due to the superposition of COVID-19 and national drug gathering and other factors, the company achieved operating income of 33 billion 683 million yuan, down 4.97% year-on-year, and realized a net profit of 2 billion 820 million yuan attributable to shareholders of listed companies, an increase of 0.24% over the same period last year, and realized the attributable to shareholders of listed companies after deducting non operating net profit of 2 billion 430 million yuan, down 5.62% over the same period last year. By the end of 2020, the total assets of the company is RMB 24.201 billion, the net assets attributable to the shareholders of the parent company is RMB 14.620 billion, the asset liability ratio is 37.28%, and the return on equity (ROE) is 20.95%, which has been maintained at more than 20% for 14 consecutive years.
According to the announcement, the total remuneration of directors, supervisors and senior managers during the reporting period was 12.75 million yuan. Lu Liang, chairman of the board, received 2.4 million yuan of pre tax remuneration from the company, Li Yuedong, director and general manager, 1.5 million yuan of pre tax remuneration from the company, Qiu Renbo, financial director, 1.2 million yuan of pre tax remuneration from the company, and Chen Bo, Secretary of the board, 1.2 million yuan of pre tax remuneration from the company.
According to digbei.com, after more than 20 years of development, Huadong pharmaceutical has developed into a large comprehensive pharmaceutical listed company integrating pharmaceutical research and development, production and distribution.